Article
Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2021
Fan Chengjuan, Zhao Qiuyu, Li Li, Shen Weixi, Du Yang, Teng Chong, Gao Feng, Song Xiaowei, Jiang Qiuying, Huang Dayong, Jin Yinghua, Lv Yanju, Wei Lingxiao, Shi Tengfei, Zhao Xue, Gao Naisheng, Jiang Zhengjun, Xin Tao
Abstract excerpt
INTRODUCTION: We aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating EGFR-mutant leptomeningeal metastases (LMs) from EGFR-mutant NSCLC. METHODS: Patients with EGFR-mutant NSCLC with LM who had failed tyrosine kinase inhibitors were recruited. The dose of IP was escalated from 15 mg to 80 mg using an accelerated titration design in a phase 1 study. The recommended dose (RD)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.